Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.

Cells · 2025 · PMC11988809 · PMID 40214505

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Our findings contribute to the growing body of evidence that immune checkpoint markers, particularly CTLA-4, TIGIT, TIM-3, and PD-1, may be significant in the immunopathology of MS.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.